Related references
Note: Only part of the references are listed.Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
Helmut Sies et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Progression-Related Loss of Stromal Caveolin 1 Levels Mediates Radiation Resistance in Prostate Carcinoma via the Apoptosis Inhibitor TRIAP1
Julia Ketteler et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade
Michelle M. Williams et al.
MOLECULAR CANCER RESEARCH (2017)
Progression-related loss of stromal Caveolin 1 levels fosters the growth of human PC3 xenografts and mediates radiation resistance
Andrej Panic et al.
SCIENTIFIC REPORTS (2017)
Oxidative Stress
Helmut Sies et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 86 (2017)
Targeted Inhibition of Glutamine-Dependent Glutathione Metabolism Overcomes Death Resistance Induced by Chronic Cycling Hypoxia
Johann Matschke et al.
ANTIOXIDANTS & REDOX SIGNALING (2016)
Extracellular Adenosine Production by ecto-5′-Nucleotidase (CD73) Enhances Radiation-Induced Lung Fibrosis
Florian Wirsdoerfer et al.
CANCER RESEARCH (2016)
Hypoxic control of metastasis
Erinn B. Rankin et al.
SCIENCE (2016)
Deubiquitylating enzyme USP9x regulates radiosensitivity in glioblastoma cells by Mcl-1-dependent and -independent mechanisms
F. Wolfsperger et al.
CELL DEATH & DISEASE (2016)
Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC
Marion Gilormini et al.
ONCOTARGET (2016)
Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy
Byeong Mo Kim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
Thomas J. Kipps et al.
LEUKEMIA & LYMPHOMA (2015)
Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis
B. Wang et al.
CELL DEATH AND DIFFERENTIATION (2014)
The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells
Bin Wang et al.
MOLECULAR CANCER (2014)
Ionizing Radiation Sensitizes Breast Cancer Cells to Bcl-2 Inhibitor, ABT-737, through Regulating Mcl-1
Hao Wu et al.
RADIATION RESEARCH (2014)
The Stress Protein BAG3 Stabilizes Mcl-1 Protein and Promotes Survival of Cancer Cells and Resistance to Antagonist ABT-737
Mariana Boiani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Past, present, and future of radiotherapy for the benefit of patients
Juliette Thariat et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Charles M. Rudin et al.
CLINICAL CANCER RESEARCH (2012)
The Intrinsic Apoptosis Pathways as a Target in Anticancer Therapy
Verena Jendrossek
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2012)
Imaging hypoxia to improve radiotherapy outcome
Michael R. Horsman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Hypoxia-Induced Modulation of Apoptosis and BCL-2 Family Proteins in Different Cancer Cell Types
Audrey Sermeus et al.
PLOS ONE (2012)
Deubiquitinase USP9x Confers Radioresistance through Stabilization of Mcl-1
Donatella Trivigno et al.
NEOPLASIA (2012)
Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells
Christoph Wohlkoenig et al.
CANCER LETTERS (2011)
The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy
P. N. Kelly et al.
CELL DEATH AND DIFFERENTIATION (2011)
Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1
Luke R. E. Harrison et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Leena Gandhi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Novel Bcl-2 Inhibitor ABT-737 Is More Effective in Hypoxia and Is Able to Reverse Hypoxia-Induced Drug Resistance in Neuroblastoma Cells
Tetyana Klymenko et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Mechanisms of Drug-Induced Mitotic Catastrophe in Cancer Cells
Jose Portugal et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Hypoxia Suppression of Bim and Bmf Blocks Anoikis and Luminal Clearing during Mammary Morphogenesis
Kelly A. Whelan et al.
MOLECULAR BIOLOGY OF THE CELL (2010)
Strong association between cancer and genomic instability
Christian Streffer
RADIATION AND ENVIRONMENTAL BIOPHYSICS (2010)
BCL-xL Is a Target Gene Regulated by Hypoxia-inducible Factor-1α
Ni Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Hypoxia in cancer: significance and impact on clinical outcome
Peter Vaupel et al.
CANCER AND METASTASIS REVIEWS (2007)
Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor
J Lanzen et al.
CANCER RESEARCH (2006)
Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis
JP Piret et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Hypoxia-mediated down-regulation of bid and bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance
JT Erler et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways
M Weinmann et al.
FASEB JOURNAL (2004)
Timeline - Radiation oncology: a century of achievements
J Bernier et al.
NATURE REVIEWS CANCER (2004)
Expression of p53 protein and the apoptotic regulatory molecules Bcl-2, Bcl-XL, and Bax in locally advanced squamous cell carcinoma of the lung
MS Shabnam et al.
LUNG CANCER (2004)
Tumor microenvironmental physiology and its implications for radiation oncology
P Vaupel
SEMINARS IN RADIATION ONCOLOGY (2004)
Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-x(L) in resected non-small-cell lung cancers
AM Groeger et al.
HISTOPATHOLOGY (2004)
Modulation of cell death in the tumor micro environment
BG Wouters et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
Hypoxia - A key regulatory factor in tumour growth
AL Harris
NATURE REVIEWS CANCER (2002)
Share Paper
